-
Incomplete DPYD haplotype B3 in a patient with locally advanced gastric cancer: Reconsidering the 5-FU dosage strategy Eur. J. Cancer (IF 8.4) Pub Date : 2024-04-20 Sascha Dierks, Sören Matthias Buchholz, Alexander König, Torsten Liersch, Julie Schanz
-
Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers Eur. J. Cancer (IF 8.4) Pub Date : 2024-04-14 Pierre-Louis Cariou, Cédric Pobel, Jean-Marie Michot, François-Xavier Danlos, Benjamin Besse, Franck Carbonnel, Xavier Mariette, Aurélien Marabelle, Sabine Messayke, Caroline Robert, Emilie Routier, Nicolas Noël, Olivier Lambotte
Immune checkpoint blockers (ICBs) can induce immune-related adverse events (irAEs) whose management is based on expert opinion and may require the prescription of steroids and/or immunosuppressants (ISs). Recent data suggest that these treatments can reduce the effectiveness of ICBs. To investigate the relationship between the use of steroids and/or ISs and overall survival (OS) and progression-free
-
A selective anatomically based lymph node sampling can replace a side specific pelvic lymphadenectomy in endometrial cancer with failed sentinel node mapping Eur. J. Cancer (IF 8.4) Pub Date : 2024-04-12 Michele Bollino, Barbara Geppert, Celine Lönnerfors, Jan Persson
To evaluate the locations of metastatic pelvic sentinel nodes (SLN) and the proportion of SLNs outside and within defined typical anatomical positions along the upper paracervical lymphatic pathway (UPP). Consecutive women with endometrial cancer (EC) of all risk groups underwent pelvic SLN-detection using cervically injected indocyanine green (ICG). A strict anatomically based algorithm and definitions
-
Composite event-free-survival as an endpoint in oncology drug evaluation: Review and guidance perspectives from the Haute Autorité de Santé (HAS) Eur. J. Cancer (IF 8.4) Pub Date : 2024-04-12 Etienne Lengliné, Joachim Baba, Paul de Boissieu, Alexandre Beaufils, Alice Desbiolles, Thierno Diatta, Pierre Cochat, Sylvie Chevret
The use of right-censored composite endpoints, such as progression-free survival, has been questioned in haemato-oncology trials due to potential bias in estimated treatment effect. This may impact the accuracy of health technology evaluations. We hypothesized that there is heterogeneity and potential sources of bias in the reporting of composite endpoints to health technology assessment (HTA) bodies
-
Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ Eur. J. Cancer (IF 8.4) Pub Date : 2024-04-12 Elena Guerini-Rocco, Federica Bellerba, Alberto Concardi, Sergio Vincenzo Taormina, Giulio Cammarata, Caterina Fumagalli, Aliana Guerrieri-Gonzaga, Debora Macis, Eliza Del Fiol Manna, Emanuela Balladore, Maria Cannone, Paolo Veronesi, Nicola Fusco, Bernardo Bonanni, Giuseppe Viale, Massimo Barberis, Sara Gandini, Matteo Lazzeroni
Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer with highly variable clinical behavior, but risk stratification is still challenging. We sought to identify immune-related gene expression signatures of pure DCIS associated with different risks of breast cancer recurrence. A retrospective nested case-control study of 143 pure DCIS was performed including 70 women
-
Unresectable biliary tract cancer: Current and future systemic therapy Eur. J. Cancer (IF 8.4) Pub Date : 2024-04-12 Danmei Zhang, Klara Dorman, C. Benedikt Westphalen, Michael Haas, Steffen Ormanns, Jens Neumann, Max Seidensticker, Jens Ricke, Enrico N. De Toni, Frederick Klauschen, Hana Algül, Timo Reisländer, Stefan Boeck, Volker Heinemann
For decades, treatment of advanced biliary tract cancer (BTC) was confined to the use of chemotherapy. In recent years however, the number of therapeutic options available for patients with unresectable BTC have drastically increased, with immunotherapy and targeted treatment gradually joining the ranks of guideline-recommended treatment regimens. The aim of the present review is to summarise the current
-
Clinical trials of T-cell re-directing therapy in plasma cell precursor conditions Eur. J. Cancer (IF 8.4) Pub Date : 2024-04-09 Samer Al Hadidi
-
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma Eur. J. Cancer (IF 8.4) Pub Date : 2024-04-08 Lucia Carril-Ajuria, Pernelle Lavaud, Cecile Dalban, Sylvie Negrier, Gwénaëlle Gravis, Robert J. Motzer, Christine Chevreau, Nizar M. Tannir, Stéphane Oudard, David F. McDermott, Brigitte Laguerre, Hans J. Hammers, Philippe Barthelemy, Elizabeth R. Plimack, Delphine Borchiellini, Marine Gross-Goupil, Ruiyun Jiang, Chung-Wei Lee, Heshani de Silva, Brian I. Rini, Bernard Escudier, Laurence Albigès
The Lung Immune Prognostic Index (LIPI) is associated with immune checkpoint inhibitors (ICI) outcomes across different solid tumors, particularly in non-small cell lung cancer. Data regarding the prognostic and/or predictive role of LIPI in metastatic renal cell carcinoma (mRCC) are still scarce. The aim of this study was to evaluate whether LIPI could be predictive of survival in mRCC patients. We
-
Oncological outcomes after a pathological complete response following total neoadjuvant therapy or chemoradiotherapy for high-risk locally advanced rectal cancer in the RAPIDO trial Eur. J. Cancer (IF 8.4) Pub Date : 2024-04-07 Wouter H. Zwart, Sofieke J.D. Temmink, Geke A.P. Hospers, Corrie A.M. Marijnen, Hein Putter, Iris D. Nagtegaal, Lennart Blomqvist, Elma Meershoek-Klein Kranenbarg, Annet G.H. Roodvoets, Anna Martling, Cornelis J.H. van de Velde, Bengt Glimelius, Koen C.M.J. Peeters, Boudewijn van Etten, Per J. Nilsson, Collaborative investigators
A pathological complete response (pCR) following chemoradiation (CRT) or short-course radiotherapy (scRT) leads to a favourable prognosis in patients with rectal cancer. Total neo-adjuvant therapy (TNT) doubles the pCR rate, but it is unknown whether oncological outcomes remain favourable and whether the same characteristics are associated with pCR as after CRT. Comparison between patients with pCR
-
Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials Eur. J. Cancer (IF 8.4) Pub Date : 2024-04-04 Alessandra Raimondi, Young Woo Kim, Won Ki Kang, Ruth E. Langley, Yoon Young Choi, Kyoung-Mee Kim, Matthew Guy Nankivell, Giovanni Randon, Myeong-Cherl Kook, Ji Yeong An, Heike I. Grabsch, Michele Prisciandaro, Federico Nichetti, Sung Hoon Noh, Tae Sung Sohn, Sung Kim, Andrew Wotherspoon, Federica Morano, David Cunningham, Jeeyun Lee, Jae-Ho Cheong, Elizabeth Catherine Smyth, Filippo Pietrantonio
Surgery plus peri-operative/adjuvant chemotherapy is the standard of care for locally advanced GC/GEJC, though with unsatisfactory results. dMMR/MSI-high tumors have better prognosis and scant benefit from chemotherapy as compared to pMMR/MSS ones. The differential outcome of therapies in terms of safety and efficacy according to sex is still debated in GC/GEJC patients. We previously performed an
-
Corrigendum to “Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancer” Eur. J. Cancer (201) (April) 2024, 113913 Eur. J. Cancer (IF 8.4) Pub Date : 2024-04-03 Nicholas Gravbrot, Christopher R. Weil, Cristina M. DeCesaris, David K. Gaffney, Gita Suneja, Lindsay M. Burt
-
Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-30 Valentina Tuninetti, Elisa Virano, Vanda Salutari, Andrea Ricotti, Carmela Pisano, Monika Ducceschi, Giacinto Turitto, Giuseppa Scandurra, Maria Cristina Petrella, Valeria Forestieri, Monica Rizzetto, Serafina Mammoliti, Grazia Artioli, Raffaella Cioffi, Lucia Borsotti, Marco Bellero, Chiara Rognone, Vittoria Carbone, Gabriella Ferrandina, Mara Mantiero, Carmen Azzolina, Eleonora Geninatti, Sandro
cemiplimab is an immunoglobulin G4 monoclonal antibody targeting the programmed cell death-1 receptor. A nominal use program is available in Italy in advanced cervical cancer (CC) patients treated with platinum based chemotherapy based on the results of EMPOWER-Cervical 1/GOG-3016/ENGOTcx9 trial. This real-world, retrospective cohort, multicenter study aimed at describing clinical outcomes of patients
-
Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-30 Sujith Baliga, Ahmad K. Abou-Foul, Pablo Parente, Petr Szturz, Juliette Thariat, Aditya Shreenivas, Paul Nankivell, Federica Bertolini, Julian Biau, Dukagjin Blakaj, Sinead Brennan, Aina Brunet, Thiago Bueno De Oliveira, Barbara Burtness, Alberto Carral Maseda, Velda Ling-Yu Chow, Melvin LK Chua, Mischa de Ridder, Satya Garikipati, Nobuhiro Hanai, Francis Cho Hao Ho, Shao Hui Huang, Naomi Kiyota, Konrad
The Head and Neck Cancer International Group (HNCIG) has undertaken an international modified Delphi process to reach consensus on the essential data variables to be included in a minimum database for HNC research. Endorsed by 19 research organisations representing 34 countries, these recommendations provide the framework to facilitate and harmonise data collection and sharing for HNC research. These
-
Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-30 Emanuel Bührer, David D'Haese, Gedske Daugaard, Ronald de Wit, Costantine Albany, Alexey Tryakin, Karim Fizazi, Olof Stahl, Jourik A. Gietema, Ugo De Giorgi, Fay H. Cafferty, Aaron R. Hansen, Torgrim Tandstad, Robert A. Huddart, Andrea Necchi, Christopher J. Sweeney, Xavier Garcia-Del-Muro, Daniel Y.C. Heng, Anja Lorch, Michal Chovanec, Eric Winquist, Peter Grimison, Darren R. Feldman, Angelika Terbuch
To resolve the ongoing controversy surrounding the impact of teratoma (TER) in the primary among patients with metastatic testicular non-seminomatous germ-cell tumours (NSGCT). Using the International Germ Cell Cancer Collaborative Group (IGCCCG) Update Consortium database, we compared the survival probabilities of patients with metastatic testicular GCT with TER (TER) or without TER (NTER) in their
-
Response to letter entitled: Re: Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-29 James A. Thomas, Bradley J. Kendall, Graeme A. Macdonald, Aaron P. Thrift
-
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-27 Theresa Ruf, Rafaela Kramer, Andrea Forschner, Ulrike Leiter, Friedegund Meier, Lydia Reinhardt, Pia Dücker, Carolin Ertl, Dirk Tomsitz, Julia K. Tietze, Ralf Gutzmer, Evelyn Dabrowski, Lisa Zimmer, Anja Gesierich, Sarah Zierold, Lars E. French, Thomas Eigentler, Teresa Amaral, Lucie Heinzerling
Immune checkpoint inhibitors (ICI) induce adverse events (irAEs) that do not respond to steroids, i.e. steroid-refractory (sr) irAEs, and irAEs in which steroids cannot be tapered, i.e. steroid-dependent (sd) irAEs, in about 10% of cases. An evidence-based analysis of the effectiveness of second-line immunosuppressive agents with regard to irAE and tumor control is lacking. The international web-based
-
Response to Letter RE: Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-27 Pien Debets, Koen M.A. Dreijerink, Anton Engelsman, Max Dahele, Harm R. Haak, Rebecca V. Steenaard, Ellen Kapiteijn, Eleonora Corssmit, Willemien Menke – van der Houven van Oordt
-
Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-26 Nicolas Roussot, Guillaume Constantin, Isabelle Desmoulins, Anthony Bergeron, Laurent Arnould, Françoise Beltjens, Didier Mayeur, Courèche Kaderbhai, Audrey Hennequin, Clémentine Jankowski, Marie Martine Padeano, Hélène Costaz, Sarah Jacinto, Eloise Michel, Alix Amet, Charles Coutant, Brigitte Costa, Christelle Jouannaud, Mathilde Deblock, Christelle Levy, Jean-Marc. Ferrero, Pierre Kerbrat, Etienne
The CPS+EG scoring system was initially described in unselected early breast cancer (eBC) patients treated with neoadjuvant chemotherapy (NAC), leading to refined prognostic stratification, and thus helping to select patients for additional post-NAC treatments. It remains unknown whether the performance is the same in new biological breast cancer entities such as the HER2-low subtype. Outcomes (disease-free
-
REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-22 Alberto Picca, Mehdi Touat, Lisa Belin, Carole Gourmelon, Vincent Harlay, Stefania Cuzzubbo, Elizabeth Cohen-Jonathan Moyal, Charlotte Bronnimann, Anna Luisa Di Stefano, Isaura Laurent, Julie Lerond, Catherine Carpentier, Franck Bielle, François Ducray, Caroline Dehais, POLA Network
Novel effective treatments are needed for recurrent IDH mutant high-grade gliomas (IDHm HGGs). The aim of the multicentric, single-arm, phase II REVOLUMAB trial (NCT03925246) was to assess the efficacy and safety of the anti-PD1 Nivolumab in patients with recurrent IDHm HGGs. Adult patients with IDHm WHO grade 3–4 gliomas recurring after radiotherapy and ≥ 1 line of alkylating chemotherapy were treated
-
EORTC QLQ-C30 general population normative data for the United States Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-21 Alizé A. Rogge, Gregor Liegl, Claire Snyder, Matthias Rose, Sandra Nolte, on behalf of the EORTC Quality of Life Group
The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 is a frequently used cancer-specific health-related quality of life (HRQoL) questionnaire. To aid interpretation of data obtained via EORTC QLQ-C30, general population norm data have been published for many countries. However, despite its frequent use in the United States, no normative data by sex and age exist to date.
-
A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-21 Mathilde Moreau, Emily Alouani, Clémence Flecchia, Antoine Falcoz, Claire Gallois, Edouard Auclin, Thierry André, Romain Cohen, Antoine Hollebecque, Anthony Turpin, Simon Pernot, Thérèse Masson, Frederic Di Fiore, Marie Dutherge, Thibault Mazard, Vincent Hautefeuille, Jean-Luc Van Laethem, Christelle De la Fouchardière, Géraldine Perkins, Meher Ben-Abdelghani, Francesco Sclafani, Thomas Aparicio, Stefano
One randomized phase III trial comparing chemotherapy (CT) with immune checkpoint inhibitors (ICI) has demonstrated significant efficacy of ICI in deficient DNA mismatch repair system/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer. However, few studies have compared ICI with CT in other advanced dMMR/MSI-H digestive tumors. In this multicenter study, we included patients
-
Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-20 Vadim Lesan, Timothée Olivier, Vinay Prasad
Kaplan-Meier analysis hinges on the assumption that patients who are censored– lost to follow-up, or only recently enrolled on the study– are no different, on average, than patients who are followed. As such, censoring these patients– omitting their future information and taking the average of those who were followed– should not dramatically change the overall estimate. Yet, in a recent clinical trial
-
Evolution of clinical nature, treatment and survival of locally recurrent rectal cancer: Comparative analysis of two national cross-sectional cohorts Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-20 E.G.M. van Geffen, J.M.A. Langhout, S.J.A. Hazen, T.C. Sluckin, S. van Dieren, G.L. Beets, R.G.H. Beets-Tan, W.A.A. Borstlap, J.W.A. Burger, K. Horsthuis, M.P.W. Intven, A.G.J. Aalbers, K. Havenga, A.W.K.S. Marinelli, J. Melenhorst, J. Nederend, H.M.U. Peulen, H.J.T. Rutten, W.H. Schreurs, J.B. Tuynman, C. Verhoef, J.H.W. de Wilt, C.A.M. Marijnen, P.J. Tanis, M. Kusters, on behalf of the Dutch Snapshot
In the Netherlands, use of neoadjuvant radiotherapy for rectal cancer declined after guideline revision in 2014. This decline is thought to affect the clinical nature and treatability of locally recurrent rectal cancer (LRRC). Therefore, this study compared two national cross-sectional cohorts before and after the guideline revision with the aim to determine the changes in treatment and survival of
-
Performance of an automated total body mapping algorithm to detect melanocytic lesions of clinical relevance Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-19 Julia K. Winkler, Katharina S. Kommoss, Ferdinand Toberer, Alexander Enk, Lara V. Maul, Alexander A. Navarini, Jeremy Hudson, Gabriel Salerni, Albert Rosenberger, Holger A. Haenssle
Total body photography for skin cancer screening is a well-established tool allowing documentation and follow-up of the entire skin surface. Artificial intelligence-based systems are increasingly applied for automated lesion detection and diagnosis. In this prospective observational international multicentre study experienced dermatologists performed skin cancer screenings and identified clinically
-
Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-19 Rikke B. Holmstroem, Sidsel Pedersen, Rebecca Jurlander, Kasper Madsen, Marco Donia, Christina H. Ruhlmann, Henrik Schmidt, Charlotte A. Haslund, Lars Bastholt, Inge Marie Svane, Eva Ellebaek
Clinical trials have demonstrated promising outcomes for adjuvant immunotherapy in patients with resected melanoma. Real-life data provide valuable insights to support patient guidance and treatment decisions. Observational population-based study examining a national cohort of patients with resected stage III-IV melanoma referred for adjuvant therapy. Data were extracted from the Danish Metastatic
-
Scaling up and implementing the digital Survivorship Passport tool in routine clinical care – The European multidisciplinary PanCareSurPass project Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-19 Anna-Liesa Filbert, Leontien Kremer, Ruth Ladenstein, Catherine Chronaki, Alexander Degelsegger-Márquez, Heleen van der Pal, Edit Bardi, Anne Uyttebroeck, Thorsten Langer, Monica Muraca, Adela Cañete Nieto, Jelena Rascon, Francesca Bagnasco, Stefan Beyer, Jeroen te Dorsthorst, Samira Essiaf, Antonio Orduña Galan, Anita Kienesberger, Kylie O’Brien, Marisa Correcher Palau, Saskia M.F. Pluijm, Sonia di
Childhood cancer survivors (CCS), of whom there are about 500,000 living in Europe, are at an increased risk of developing health problems [1–6] and require lifelong Survivorship Care. There are information and knowledge gaps among CCS and healthcare providers (HCPs) about requirements for Survivorship Care [7–9] that can be addressed by the Survivorship Passport (SurPass), a digital tool providing
-
Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-19 Daniel L. Hertz, Markus Joerger, Yung-Jue Bang, Ron H. Mathijssen, Caicun Zhou, Li Zhang, David Gandara, Michael Stahl, Bradley J. Monk, Ulrich Jaehde, Jan H. Beumer
Paclitaxel, one of the most frequently used anticancer drugs, is dosed by body surface area, which leads to substantial inter-individual variability in systemic drug exposure. We evaluated clinical evidence regarding the scientific rationale and clinical benefit of individualized paclitaxel dosing based on measured systemic concentrations, known as therapeutic drug monitoring (TDM). In retrospective
-
Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: A nationwide, population-based cohort study Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-17 Thomas Wagner, Birgitte Grønkær Toft, Jakob Lauritsen, Mikkel Bandak, Ib Jarle Christensen, Birte Engvad, Michael Kreiberg, Mads Agerbæk, Lars Dysager, Andreas Carus, Josephine Julie Rosenvilde, Daniel Berney, Gedske Daugaard
Approximately 30% of patients with clinical stage I non-seminoma (CSI-NS) relapse. Current risk stratification is based on lymphovascular invasion (LVI) alone. The extent to which additional tumor characteristics can improve risk prediction remains unclear. To determine the most important prognostic factors for relapse in CSI-NS patients. Population-based cohort study including all patients with CSI-NS
-
Cisplatin shortage results in substitution of more expensive treatments: Drug cost analysis Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-16 Michael Lam, Timothée Olivier, Alyson Haslam, Jordan Tuia, Vinay Prasad
-
Novel use of abatacept and ruxolitinib as salvage therapy in steroid-refractory immune checkpoint blockade-induced myocarditis with myasthenia and myositis overlap syndrome Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-16 Stefano H. Byer, Colten Stewart, Shareef Mansour, Udhayvir S. Grewal
-
Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-16 Rémy Barbe, Younes Belkouchi, Yves Menu, Romain Cohen, Clemence David, Michele Kind, Sana Harguem, Lama Dawi, Joya Hadchiti, Fatine Selhane, Nicolas Billet, Samy Ammari, Ambroise Bertin, Littisha Lawrance, Baptiste Cervantes, Antoine Hollebecque, Corinne Balleyguier, Paul-Henry Cournede, Hugues Talbot, Nathalie Lassau, Thierry Andre
This retrospective study determined survival responses to immune checkpoint inhibitors (ICIs), comparing mono- (mono) and combo-immunotherapy (combo) in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) by analyzing quantitative imaging data and clinical factors. One hundred fifty patients were included from two centers and divided into training (n = 105) and
-
Clinical care pathways of patients with biliary tract cancer: A French nationwide longitudinal cohort study Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-16 Stylianos Tzedakis, Alexandre Challine, Sandrine Katsahian, David Malka, Romain Jaquet, Ugo Marchese, Martin Gaillard, Romain Coriat, Alix Dhote, Vincent Mallet, Heithem Jeddou, Karim Boudjema, David Fuks, Andrea Lazzati
Although the incidence of BTC is raising, national healthcare strategies to improve care lack. We aimed to explore patient clinical care pathways and strategies to improve biliary tract cancer (BTC) care. We analysed the French National Healthcare database of all BTC inpatients between January 1, 2017 and December 31, 2021. Multinomial logistic regression adjusted odds ratios (aOR) were used to identify
-
A recurrent NTRK1 tyrosine kinase domain mutation pair is characteristic in a subset of dedifferentiated liposarcomas Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-14 Zoltán Lippai, Bálint Péterfia, Gergő Papp, Katalin Dezső, Gábor Bedics, Zsuzsanna Pápai, Meindert H. Lamers, Rosan CM Kuin, Károly Szuhai, Zoltán Sápi
Dedifferentiated liposarcoma (DDLPS) is a common form of liposarcoma with challenging treatment modalities. Pan-TRK immunopositivity can be often observed without gene fusion in soft tissue sarcomas with myogenic differentiation. Expression and the role of in DDLPS are under-studied. We sought to identify activating mutations of the genes. 131 DDLPS patients were selected for pan-TRK immunohistochemistry
-
Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT) Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-13 Gael S. Roth, Loic Verlingue, Matthieu Sarabi, Jean-Frédéric Blanc, Emmanuel Boleslawski, Karim Boudjema, Anne-Laure Bretagne-Bignon, Marine Camus-Duboc, Romain Coriat, Gilles Créhange, Thierry De Baere, Christelle de la Fouchardière, Clarisse Dromain, Julien Edeline, Maximiliano Gelli, Boris Guiu, Samy Horn, Valérie Laurent-Croise, Côme Lepage, Astrid Lièvre, Anthony Lopez, Sylvain Manfredi, Julie
This document is a summary of the French intergroup guidelines of the management of biliary tract cancers (BTC) (intrahepatic, perihilar and distal cholangiocarcinomas, and gallbladder carcinomas) published in September 2023, available on the website of the French Society of Gastroenterology (SNFGE) (www.tncd.org). This collaborative work was conducted under the auspices of French medical and surgical
-
Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-11 Hildur Helgadottir, Alexios Matikas, Josefin Fernebro, Jan-Erik Frödin, Simon Ekman, Kenny A. Rodriguez-Wallberg
-
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-11 Joseph J. Sacco, Richard Jackson, Pippa Corrie, Sarah Danson, T.R. Jeffry Evans, Sebastian Ochsenreither, Satish Kumar, Andrew Goodman, James Larkin, Ioannis Karydis, Neil Steven, Paul Lorigan, Ruth Plummer, Poulam Patel, Eftychia Psarelli, Anna Olsson-Brown, Heather Shaw, Serge Leyvraz, Louise Handley, Charlotte Rawcliffe, Paul Nathan
The MAPK pathway is constitutively activated in uveal melanoma (UM). Selumetinib (AZD6244, ARRY-142886), a MEK inhibitor, has shown limited activity as monotherapy in metastatic UM. Pre-clinical studies support synergistic cytotoxic activity for MEK inhibitors combined with taxanes, and here we sought to assess the clinical efficacy of combining selumetinib and paclitaxel. Seventy-seven patients with
-
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-11 Ulka N. Vaishampayan, Marianne Keessen, Robert Dreicer, Elisabeth I. Heath, Tomas Buchler, Péter F. Árkosy, Tibor Csöszi, Pawel Wiechno, Evgeny Kopyltsov, Sergey V. Orlov, Alexey Plekhanov, Maria Smagina, Sergei Varlamov, Neal D. Shore
ModraDoc006, an oral formulation of docetaxel, is co-administered with the cytochrome P450–3A4 and P-glycoprotein inhibitor, ritonavir (r): ModraDoc006/r. The preliminary efficacy and safety of oral ModraDoc006/r was evaluated in a global randomized phase II trial and compared to the current standard chemotherapy regimen of intravenous (i.v.) docetaxel and prednisone. 103 mCRPC patients, chemotherapy-naïve
-
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-11 Alessandro Leonetti, Fabiana Perrone, Matteo Puntoni, Giuseppe Maglietta, Paola Bordi, Emilio Bria, Emanuele Vita, Francesco Gelsomino, Andrea De Giglio, Alain Gelibter, Marco Siringo, Francesca Mazzoni, Enrico Caliman, Carlo Genova, Federica Bertolini, Giorgia Guaitoli, Francesco Passiglia, Marco Donatello Delcuratolo, Michele Montrone, Giulio Cerea, Giulia Pasello, Elisa Roca, Lorenzo Belluomini
-
Prognosis of glioblastoma patients improves significantly over time interrogating historical controls Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-11 A. Thomas-Joulié, S. Tran, L. El Houari, A. Seyve, F. Bielle, C. Birzu, F. Lozano-Sanchez, K. Mokhtari, M. Giry, Y. Marie, F. Laigle-Donadey, C. Dehais, C. Houillier, D. Psimaras, A. Alentorn, A. Laurenge, M. Touat, M. Sanson, K. Hoang-Xuan, A. Kas, L. Rozenblum, M.-O. Habert, L. Nichelli, D. Leclercq, D. Galanaud, J. Jacob, C. Karachi, L. Capelle, A. Carpentier, B. Mathon, L. Belin, A. Idbaih
Glioblastoma (GBM) is the most common devastating primary brain cancer in adults. In our clinical practice, median overall survival (mOS) of GBM patients seems increasing over time. To address this observation, we have retrospectively analyzed the prognosis of 722 newly diagnosed GBM patients, aged below 70, in good clinical conditions (i.e Karnofsky Performance Status –KPS- above 70%) and treated
-
Assessing the clinical benefit of systemic anti-cancer treatments in the Netherlands: The impact of different thresholds for effectiveness Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-11 Brenda Leeneman, Nicolas S.H. Xander, W. Edward Fiets, Wouter K. de Jong, Nathalie E.M. Uyl, A.N. Machteld Wymenga, An K.L. Reyners, Carin A. Uyl-de Groot
In the Netherlands, the clinical benefit of systemic anti-cancer treatments (SACTs) is assessed by the Committee for the Evaluation of Oncological Agents (cieBOM). For non-curative SACTs, the assessment is based on the hazard ratio (HR) for progression-free survival and/or overall survival (OS), and the difference in median survival. We evaluated the impact of different thresholds for effectiveness
-
Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter? Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-11 Patricia Raiser, Gudrun Schleiermacher, Marion Gambart, Benoit Dumont, Anne-Sophie Defachelles, Estelle Thebaud, Julie Tandonnet, Claudia Pasqualini, Stéphanie Proust, Natacha Entz-Werle, Isabelle Aerts, Lee A. Ndounga-Diakou, Arnaud Petit, Chloe Puiseux, Camille Khanfar, Jeremie Rouger, Ludovic Mansuy, Joy Benadiba, Frédéric Millot, Claire Pluchart, Salim Laghouati, Birgit Geoerger, Gilles Vassal
Addition of anti-GD2 antibodies to temozolomide-based chemotherapy has demonstrated increased antitumor activity and progression-free survival in patients with relapsed/progressive high-risk neuroblastoma. However, chemo-immunotherapy is not yet approved for this indication. This study presents the chemo-immunotherapy experience in patients with relapsed/progressive high-risk neuroblastoma treated
-
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-11 Xiaoting Wei, Zhengyun Zou, Weizhen Zhang, Meiyu Fang, Xiaoshi Zhang, Zhiguo Luo, Jing Chen, Gang Huang, Peng Zhang, Ying Cheng, Jiwei Liu, Jiyan Liu, Junping Zhang, Di Wu, Yu Chen, Xiaobiao Ma, Hongming Pan, Renbing Jiang, Xinlan Liu, Xiubao Ren, Hongqi Tian, Zhongwei Jia, Jun Guo, Lu Si
-mutant melanoma is an aggressive subtype with poor prognosis; however, there is no approved targeted therapy to date worldwide. We conducted a multicenter, single-arm, phase II, pivotal registrational study that evaluated the efficacy and safety of the MEK inhibitor tunlametinib in patients with unresectable, stage III/IV, NRAS-mutant melanoma (NCT05217303). The primary endpoint was objective response
-
How to develop new systemic treatments in ultra-rare cancers with high unmet needs? The case of alveolar soft-part sarcoma Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-11 Silvia Stacchiotti, Gauthier Bouche, Ralf Herold, Pan Pantziarka, Kathrin Schuster, Roger Wilson, Francesco Pignatti, Bernd Kasper
Developing new drugs or generating evidence for existing drugs in new indications for ultra-rare cancers is complex and carries a high-risk of failure. This gets even harder in ultra-rare tumours, which have an annual incidence of 1 per 1,000,000 population or less. Here, we illustrate the problem of adequate evidence generation in ultra-rare tumours, using Alveolar Soft-Part Sarcomas (ASPS) – an ultra-rare
-
Corrigendum to “Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial” [Eur J Cancer 199 (2024) 113531] Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-09 Anna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, Pier Francesco Ferrucci, Michele Guida, Pietro Quaglino, Massimo Guidoboni, Paolo Marchetti, Elena Simonetti, Federica Santangelo, Giovanni Amato, Alessia Covre, Roberto Camerini, Monica Valente, Mario Mandalà, Diana Giannarelli, Luana Calabrò, Michele Maio
-
Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-08 Julian Kött, Noah Zimmermann, Tim Zell, Alessandra Rünger, Isabel Heidrich, Glenn Geidel, Daniel J. Smit, Inga Hansen, Finn Abeck, Dirk Schadendorf, Alexander Eggermont, Susana Puig, Axel Hauschild, Christoffer Gebhardt
-
Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP) Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-07 Ilse A.C. Spiekman, Laurien J. Zeverijn, Birgit S. Geurts, Karlijn Verkerk, Soemeya F. Haj Mohammad, Vincent van der Noort, Paul Roepman, Wendy W.J. de Leng, Anne M.L. Jansen, Elske C. Gootjes, Derk-Jan A. de Groot, Emile D. Kerver, Theo van Voorthuizen, Jeanine M.L. Roodhart, Liselot B.J. Valkenburg-van Iersel, Hans Gelderblom, Emile E. Voest, Henk M.W. Verheul
In 2–5% of patients with colorectal cancer (CRC), human epidermal growth factor 2 ( is amplified or overexpressed. Despite prior evidence that anti-HER2 therapy confers clinical benefit (CB) in one-third of these patients, it is not approved for this indication in Europe. In the Drug Rediscovery Protocol (DRUP), patients are treated with off-label drugs based on their molecular profile. Here, we present
-
-
FGF amplification an important targeted for head and neck cancer patient? A case report of a patient with FGF amplification treated with erdafitinib Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-02 Nyere Gibson, Mathieu Larroquette, Charlotte Domblides, Felix Lefort, Amaury Daste
-
Corrigendum to “Risk factors for early-onset pancreatic ductal adenocarcinoma: A systematic literature review” [Eur J Cancer 198 (2024) 113471] Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-02 Sreenivasa R. Chandana, Laura M. Woods, Fiona Maxwell, Ruth Gandolfo, Tanios Bekaii-Saab
-
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-02 Romain Boidot, Michael G.B. Blum, Marie-Pierre Wissler, Céline Gottin, Jiri Ruzicka, Sandy Chevrier, Tiffany M. Delhomme, Jérome Audoux, Adrien Jeanniard, Pierre-Alexandre Just, Philipp Harter, Sandro Pignata, Antonio González-Martin, Christian Marth, Johanna Mäenpää, Nicoletta Colombo, Ignace Vergote, Keiichi Fujiwara, Nicolas Duforet-Frebourg, Denis Bertrand, Nicolas Philippe, Isabelle Ray-Coquard
The PAOLA-1/ENGOT-ov25 trial showed that maintenance olaparib plus bevacizumab increases survival of advanced ovarian cancer patients with homologous recombination deficiency (HRD). However, decentralized solutions to test for HRD in clinical routine are scarce. The goal of this study was to retrospectively validate on tumor samples from the PAOLA-1 trial, the decentralized SeqOne assay, which relies
-
The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-02 Katrin Schaper-Gerhardt, Ralf Gutzmer, Yenny Angela, Lisa Zimmer, Elisabeth Livingstone, Dirk Schadendorf, Jessica C. Hassel, Carsten Weishaupt, Bernhard Remes, Linda Kubat, Ivelina Spassova, Jürgen C. Becker
Recent evidence suggests additional immunomodulatory properties of RANKL inhibition possibly boosting the clinical efficacy of immune checkpoint inhibitors (ICI). We conducted a prospective, multicentre clinical trial in unresectable stage IV melanoma patients with bone metastases who received denosumab in parallel with dual ICI (BONEMET) and performed comprehensive immune monitoring at baseline and
-
Propranolol monotherapy in angiosarcoma – A window-of-opportunity study (PropAngio) Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-02 Alaa Embaby, Kimberley M. Heinhuis, Nikki S. IJzerman, Anne Miek Koenen, Stephanie van der Kleij, Ingrid Hofland, Hester van Boven, Joyce Sanders, Winette T.A. van der Graaf, Rick L. Haas, Alwin D.R. Huitema, Winan J. van Houdt, Neeltje Steeghs
-
Clinical and prognostic differences in oropharyngeal squamous cell carcinoma in USA and Denmark, two HPV high-prevalence areas Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-02 Amanda-Louise Fenger Carlander, Simone Kloch Bendtsen, Jacob H. Rasmussen, Kathrine Kronberg Jakobsen, Martin Garset-Zamani, Christian Grønhøj, Jeppe Friborg, Katherine Hutcheson, Faye M. Johnson, Clifton D. Fuller, Amy C. Moreno, Toyin Babarinde, Neil D. Gross, Jeffrey N. Myers, Christian von Buchwald
Uncertainty persists regarding clinical and treatment variations crucial to consider when comparing high human papillomavirus (HPV)-prevalence oropharyngeal squamous cell carcinoma (OPSCC) cohorts for accurate patient stratification and replicability of clinical trials across different geographical areas. OPSCC patients were included from The University of Texas MD Anderson Cancer Center (UTMDACC)
-
Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-02 Hang Cao, Zelin Ma, Qingyuan Huang, Han Han, Yuan Li, Yang Zhang, Haiquan Chen
-
UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma – A phase II randomised trial Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-01 Vilde Drageset Haakensen, Åsa Kristina Öjlert, Solfrid Thunold, Saima Farooqi, Anna K. Nowak, Wee L. Chin, Oscar Grundberg, Weronika Maria Szejniuk, Susana Cedres, Jens Benn Sørensen, Tonje Sofie Dalen, Marius Lund-Iversen, Maria Bjaanæs, Åslaug Helland
The NIPU-trial investigates the effect of adding the telomerase vaccine UV1 to treatment with ipilimumab and nivolumab for patients with pleural mesothelioma (PM). In this phase 2 open-label trial, patients with PM progressing after first-line chemotherapy were randomised to receive ipilimumab and nivolumab alone (arm B) or combined with UV1 (arm A). The primary endpoint was progression-free survival
-
A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-01 Takayuki Yoshino, Naushin Hooda, Diana Younan, Kei Muro, Kohei Shitara, Volker Heinemann, Bert Howard O’neil, Fernando Rivera Herrero, Marc Peeters, Junpei Soeda, Mina Suh, Heidi Reichert, Khalid Mezzi, Jon Fryzek, Victoria Chia, Marko Rehn, Sebastian Stintzing
The first-line treatment choice of EGFRIs plus doublet chemotherapy vs. bevacizumab plus doublet chemotherapy remains a topic of interest for patients with left-sided RAS WT mCRC. We conducted a systematic literature review and meta-analysis of clinical trial data published between 2015 and 2024. We evaluated the relative efficacy and safety of first-line EGFRIs plus doublet chemotherapy (FOLFIRI or
-
Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-01 Michael Untch, David Pérol, Erica L. Mayer, Javier Cortes, Arnd Nusch, David Cameron, Carlos Barrios, Thomas Delea, Andrii Danyliv, Namita Mishra, Rhea Gupta, Purnima Pathak, Peter A. Fasching
Overall survival (OS) is a universally accepted measure of clinical benefit; however, prolonged follow-up is needed to observe sufficient events. Disease-free survival (DFS) has been widely adopted as a primary endpoint for early breast cancer (EBC) trials, as follow-up is comparatively shorter. Here, we present an analysis evaluating DFS as a surrogate for OS for adjuvant treatment of hormone rec
-
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-01 Lea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, Jessica C. Hassel, Michael Erdmann, Andrea Forschner, Douglas B. Johnson, Renáta Váraljai, Georg Lodde, Jan Malte Placke, Frederik Krefting, Anne Zaremba, Selma Ugurel, Alexander Roesch, Carsten Schulz, Carola Berking, Christoph Pöttgen, Alexander M. Menzies, Georgina V. Long, Reinhard Dummer, Elisabeth Livingstone, Dirk Schadendorf, Lisa Zimmer
Effective treatment options are limited for patients with advanced melanoma who have progressed on immune checkpoint inhibitors (ICI) and targeted therapies (TT). Preclinical models support the combination of ICI with TT; however, clinical trials evaluating the efficacy of triplet combinations in first-line setting showed limited advantage compared to TT only. We conducted a retrospective, multicenter
-
Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-01 Liangshun You, Yi Liu, Wenyuan Mai, Wanzhuo Xie, De Zhou, Liping Mao, Lili Chen, Xinping Zhou, Liya Ma, Xiaolong Zheng, Juying Wei, Yinjun Lou, Xingnong Ye, Hongyan Tong, Jie Jin, Haitao Meng
The outcome of relapsed/refractory (R/R) acute myeloid leukemia (AML) remains extremely poor. Venetoclax (VEN)-based regimens have shown promise in treating R/R AML. This phase 2 study aimed to systematically evaluate the efficacy and safety of the VAA regimen (VEN plus Cytarabine and Azacitidine) in R/R AML patients. Thirty R/R AML patients were enrolled. The study adopted a stepwise ramp-up of VEN
-
Survival trends for patients diagnosed with cutaneous malignant melanoma in the Nordic countries 1990-2016: The NORDCAN survival studies Eur. J. Cancer (IF 8.4) Pub Date : 2024-03-01 Frida E. Lundberg, Helgi Birgisson, Gerda Engholm, Elínborg J. Ólafsdóttir, Lina Steinrud Mørch, Tom Børge Johannesen, David Pettersson, Mats Lambe, Karri Seppä, Paul C. Lambert, Anna L.V. Johansson, Lisbet Rosenkrantz Hölmich, Therese M.-L. Andersson
The survival in patients diagnosed with cutaneous malignant melanoma (CMM) has improved in the Nordic countries in the last decades. It is of interest to know if these improvements are observed in all ages and for both women and men. Patients diagnosed with CMM in the Nordic countries in 1990–2016 were identified in the NORDCAN database. Flexible parametric relative survival models were fitted, except